ClinicalTrials.gg
RecruitingNCT05942547Updated Jul 12, 2023

the Efficacy and Safety of Diosmin on Non-diabetic Patients With Non-alcoholic Steatohepatitis.

A Phase 3 interventional study of Diosmin and Placebo in Non Alcoholic Steatohepatitis, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-12.

Sponsored by Tanta University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years 1 month ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University — 6 open to participants now, 8 under way, 4 of them phase 3. Non-alcoholic Fatty Liver Disease · Tanta University.

Planned enrollment
9th of 12
48 · median 58
Started
2023
with 2 others
Phase 3
3 of 13
2 open now
Registered
8th of 13
by date

Among the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 3 in phase 3, and was the 8th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

6 of the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, or all of them as a file.
02

Study summary

This is a randomized, controlled study evaluating diosmin tablets administered daily for 3 months. The purpose of the study is to evaluate the efficacy and safety of diosmin on non-diabetic patients with non-alcoholic steatohepatitis.

Read the detailed description

The aim of the study is to test the implication of diosmin in fatty liver disease through evaluation of its efficacy and safety in non-diabetic patients with nonalcoholic steatohepatitis (NASH).

Patients and Methods:

This study will be a randomized double-blind placebo-controlled parallel study that will involve 48 non-diabetic patients with confirmed diagnosis of NASH. The patients will be recruited from outpatient Clinic of the internal medicine department, Tanta University Hospital, Tanta, Egypt. The diagnosis of NASH will be confirmed by imaging technique (increased liver echogenicity, stronger echoes in the hepatic parenchyma, vessel blurring, and narrowing of the lumen of the hepatic veins), mild to moderate elevation in aminotransferase activities (>2 but \<5 times upper limit of normal), hepatic steatosis index (HIS) >36, HAIR score (hypertension, alanine aminotransferase level, insulin resistance) of 2 or 3 and cytokeratin-18 level >240 IU/L. The patients will be randomized in a 1:1 ratio by a neutral researcher using sealed envelopes methods with assignment codes for each available allocation to receive either diosmin 600 mg twice daily (Diosmin group; n = 24) or placebo twice daily (Placebo group; n = 24). The study duration will be 12 weeks.

  • All participants and will be informed about the benefits and risks of the study. The expected risks that will be clarified to patients include diosmin related adverse effect; stomach pain, diarrhea, headache, skin redness, muscle pain, and altered heart rate.
  • Any unexpected risks that will appear during the course of the research will be clarified to the participants and to the ethical committee on time. The data of the enrolled patients will be confidential.
  • All enrolled patients will give their written informed consents. The study will be carried out between june2023 and june2025.Demography and anthropometric measurements At baseline and after intervention, all participants will be submitted to medical history taking, demography (age, sex, and medication history), physical examination with heart rate evaluation, measurement of weight and height with subsequent calculation of body mass index (BMI)=[Weight (kg)÷ Height2 (m)]. 2. Ultrasonographic examination Ultrasonography of the liver will be carried out at baseline and at the end of the study by the same operator. Ultrasonography Fatty Liver Indicator (US-FLI) is a scoring system ranging 2-8 based on the intensity of liver/kidney contrast, posterior attenuation of ultrasound beam, vessel blurring, difficult visualization of gallbladder wall, and difficult visualization of the diaphragm and areas of focal sparing. NAFLD is diagnosed by the minimum score ≥2. 3. Blood samples collection and biochemical measurements Before and after the intervention, 8 ml of venous blood will be withdrawn by antecubital venipuncture from each participant after overnight fasting (12 h fasting period) between 8:30 and 10:30 a.m. into plain test tubes. Three ml of the blood samples will be used for the assessment of complete blood count. The remaining 5 ml of blood will be centrifuged at 3000 rpm for 10 min. The separated serum will be divided into two portions. The first portion will be used for immediate determination of liver panel, fasting lipid profile and fasting blood glucose concentration. The second portion of the serum will be frozen at-80°C until analysis of the remaining parameters including malondialdehyde (MDA), tumor necrosis factor- alpha (TNF-α), fasting insulin and transforming growth factor-beta1 (TGF-β1).
  • Complete blood count (CBC) will be determined by automated hematology analyzer.
  • Liver enzymes (AST, ALT, and GGT) will be determined by kinetic method.
  • Serum albumin level which will be assayed by colorimetric bromocresol green method or other available method.
  • Fasting blood glucose will be determined by glucose oxidase method or glycated hemoglobin (HbA1c%) will be measured by commercially available method
  • Lipid panel including total cholesterol (TC), triglyceride (TG) and HDLC will be assessed by enzymatic colorimetric method.
  • Fasting insulin level will be determined by ELISA.
  • Malondialdehyde (MDA) which will be assessed by colorimetric method.
  • Tumor necrosis factor- alpha (TNF-α) will be determined by ELISA.
  • Serum transforming growth factor-beta1 (TGF-β1) will be determined by ELISA.
  • In addition, prothrombin time (PT) or INR will be assessed regularly at baseline and on monthly basis. 4. Calculated parameters
  • Low density lipoprotein cholesterol (LDL-C) will be calculated using the

Friedewald formula17 as follows:

  • [LDL-C=TC- HDL-C- (TG÷5)] provided that TG level is less than 400 mg/dl.

    • Very low density lipoprotein cholesterol will be calculated using the Friedewald formula17 as follows: o VLDL = TG/5.
    • The Homeostasis Model Assessment-insulin resistance (HOMA-IR) 18 will be calculated as follow: o HOMA-IR= (Fasting glucose × fasting insulin/405) when glucose is expressed by mg/dl and insulin is expressed by μIU/ml.
    • Hepatic steatosis index "HSI".
  • Hepatic steatosis index includes gender, history of type 2 diabetes mellitus (T2DM), BMI, alanine transaminase "ALT", and aspartate transaminase "AST".
  • HSI is calculated by the following formula:

    8 × (ALT/AST ratio) + BMI + 2 if female and + 2 if diabetic (0 since the study will be conducted on non-diabetic).

  • HAIR score "hypertension, alanine aminotransferase level, insulin resistance". It is calculated from hypertension ≥140/90, ALT >40 and HOMA-IR >5.
  • Presence of one item indicates HAIR score=1. o Presence of two item indicates HAIR score=2.
  • Prescience of the 3 items indicates HAIR score=3.

    • Fibrosis risk scores: o Fibrosis index based on the 4 factors (FIB-4). FIB-4= Age (years) × AST (IU/l)/[platelet count (109

    /L) ×√ ALT (IU/l)].

  • Aspartate transaminase-to-platelet ratio index (APRI).22 APRI =AST (IU/l)/(upper limit of normal) X 100 /platelet count (109

    /L).

  • NAFLD fibrosis score (NFS) which depends on 7 parameters including age, BMI, diabetes, AST, ALT, platelets count, and albumin concentration.

    • Score \<-1.455 predicts absence of significant fibrosis (F0-F2).
    • Score ≤ - 1.455- ≤ 0.675 predicts intermediate score
    • Score > 0.675 predicts presence of significant fibrosis (F3-F4).
03

Conditions studied

  • Non Alcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-diabetic patients with or without hypertension.
  • Both males and females.
  • Age >18 years old.
  • Overweight and obese patient: (BMI) ≥ 25 kg/m2 \<.40 kg/m2
  • Patients with established diagnosis of NASH based on liver ultrasonography, mild to moderate elevation in aminotransferase activities (>2 but \<5 times ), hepatic steatosis index (HIS) >36, HAIR score of 2 or 3.

Exclusion criteria

Exclusion Criteria:

  • Patients with ≥ 40 kg/m2
  • Patients with type 2 diabetes mellitus (T2DM) on the basis of a fasting plasma glucose (FPG) level ≥ 126 mg/dl (7mmol/L) or (HbA1c) > 6.5% (48 mmol/mol).
  • Alcohol consumption greater than 20 g per day for women or greater than 30 g for men for at least three consecutive months over the past 5 years.
  • History of viral hepatitis, hemochromatosis, Wilson's disease, hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency.
  • Patients on medications interfere with lipid and carbohydrate metabolism (statin, fibrate, beta blockers, thiazide, , etc).
  • Patients with cancer or with a history of cancer.
  • Patients with thyroid disorder.
  • Patients on medications associated with steatosis such as NSAIDs, amiodarone, tamoxifen, estrogen, sodium valproate, corticosteroids, and methotrexate.
  • Patients with inflammatory diseases (rheumatoid arthritis, ulcerative colitis, etc).
  • Patients on supplements known to have antioxidant activity such as vitamin E, vitamin C, zinc, and selenium.
  • Patient with a history of cardiovascular diseases.
  • Patients with arrhythmia or altered heart rate.
  • Patients on blood thinning agents (warfarin, clopidogril, aspirin, etc), anticonvulsants (carbamazepine and phenytoin), muscle relaxants (chlorzoxazone) and non-steroidal anti-inflammatory drugs (diclofenac( in order to avoid potential pharmacodynamics and pharmacokinetic drug interactions with diosmin.
  • Pregnant and breastfeeding women.
  • Females on oral pills will be also excluded.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    diosmin group

    (Diosmin group; n = 24):will receive 600 mg twice daily

    Drug: Diosmin

  • Placebo comparator
    placebo group

    placebo group n=24 :will receive placebo twice daily

    Drug: Placebo

Interventions

  • diosmin 600mg twice daily

  • DrugPlacebo

    twice daily

06

What researchers measure

Primary outcomes

  1. the change in ultrasound including NAFLD fibrosis scor

    The change in ultrasound through decreasing liver echogenicity, Lower echoes in the hepatic parenchyma, no vessel blurring, and decrease narrowing of the lumen of the hepatic veins Ultrasonography Fatty Liver Indicator (US-FLI) \<2

    Time frame: at baseline then after 3 months

  2. The change in fibrosis risk score

    Score \<-1.455 predicts absence of significant fibrosis (F0-F2)

    Time frame: at baseline then after 3 months

Secondary outcomes

  1. The secondary outcome is the change in biological biomarkers and other measured parameters

    The change in liver panel

    Time frame: at baseline then after 3 months

  2. secondary outcome is the change in biological biomarkers and other measured parameters

    The change in the Homeostasis Model Assessment-insulin resistance (HOMA-IR)

    Time frame: at baseline then after 3 months

  3. secondary outcome is the change in biological biomarkers and other measured parameters

    The change in biological parameters (MDA, TNF-α, and TGF-β1)

    Time frame: at baseline then after 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Oct 2023, 3 months later.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Jul 12, 2023
StartEst.
Jul 10, 2023
Primary completionEst.
Oct 10, 2023
CompletionEst.
Jun 10, 2025
Last update
Jul 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05942547
Lead sponsor
Tanta University
Responsible party
Merna Tarek Elsaeed (clinical pharmacist, Tanta University) — Principal investigator
First posted
Jul 12, 2023
Start date
Jul 10, 2023 (estimated)
Primary completion
Oct 10, 2023 (estimated)
Completion
Jun 10, 2025 (estimated)
Last update
Jul 12, 2023

Study contacts

merna tarek elsaeed
Contact
sgama676@gmail.com
00201551813013
amira bahaa ismail
Contact
amira7794.aa@gmail.com
00201142760505
tarek mohamed mostafa, professor
principal investigator · Tanta University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diosmin

Start the discussion